Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'

96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials

(2013) Laurence Rimsky et al.   ANTIVIRAL THERAPY

Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies

(2013) M.R. Nelson et al.   HIV CLINICAL TRIALS

Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens

(2013) Anthony M. Mills et al.   HIV CLINICAL TRIALS

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses

(2013) S. Lambert-Niclot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Predicting antiretroviral drug resistance from the latest or the cumulative genotype

(2011) Federico Garcia et al.   ANTIVIRAL THERAPY

The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness

(2011) Rima Kulkarni et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES